CANCER PREVENTION AND CONTROL PROGRAM: PROJECT SUMMARY The scientific goals of the Cancer Prevention and Control Program (CPC) are to help alleviate the burden of cancer by elucidating the biobehavioral underpinnings of cancer risk and response, motivating lifestyle and associated changes, and informing cancer care delivery and policy. Research falls under three integrated Specific Aims: (1) identifying risks associated with cancer causation and progression; (2) intervening to improve cancer outcomes and promote survivorship; and (3) conducting health services research to advise cancer practice and policy. This programmatic work addresses molecular and social determinants of health, and eradicates disparities and cancers highly prevalent within the Catchment Area, including screening-eligible cancers. CPC is co-led by Lisa Carter-Bawa, PhD, APRN, Laura Rozek, PhD, and Kenneth Tercyak, PhD, with complementary expertise in clinical science, molecular epidemiology, and health behaviors and outcomes. The recruitment of Carter-Bawa and Rozek to CPC's leadership structure provides additional depth and strength in translating interventions to populations, and new opportunities for inter-programmatic partnerships with basic and clinical scientists. CPC includes 33 Members across 10 departments: 17 of these Members (52%) were recruited (13 strategically with 12 external, 1 internal) to the Program in the current cycle, with attention to gender, racial, and ethnic diversity. During the reporting period, CPC benefited from $17M+ in strategic investments to extend its research portfolio. Georgetown University invested an additional $1M in physical space for the Program in Washington, DC. Hackensack Meridian Health invested an additional $3M in 6,000 sq/ft of new research space for the Program in Nutley, NJ. In April 2023, CPC holds $7.5M in cancer-focused, peer-reviewed funding, of which $5.6M (75%) is from NCI, $1.4M (19%) is from other NIH sources, and $0.5M (6%) derives from additional peer-reviewed agencies. CPC's total peer-reviewed funding is $7.5M (23% over 2018). Scientific leadership roles this cycle include 17 multi-PI grants, an FDA/NIH center for tobacco regulatory science, two NCI Cancer Intervention and Surveillance Modeling Network teams, a minority/underserved Community Oncology Research Program grant, and six training-related grants (including a new NCI T32 in cancer population science) that enrich the overall mission and climate of the cancer center. In the current project period, CPC authored 348 cancer-relevant publications, of which 118 (34%) were intra-programmatic, 52 (15%) were inter-programmatic, and 12% were in high-impact (IF≥10) journals. CPC's influence has grown with the expansion of its leadership structure across the LCCC cancer research Consortium, the recruitment of highly talented and diverse early- stage and established faculty, a successful training program, and a substantial funding base. These transformations are accele...